Denali Therapeutics Inc. $DNLI Shares Purchased by Graham Capital Management L.P.

Key Points

• Graham Capital Management L.P. has increased its stake in Denali Therapeutics by 107.7%, now holding 43,005 shares valued at approximately $585,000.
• Several institutional investors have made significant investments in Denali Therapeutics, with Caitong International increasing its stake by 277% and GAMMA Investing LLC by 253.8%.
• Denali Therapeutics received a consensus rating of "Buy" from analysts, with a price target of $33.62, while recent share prices show a 4.3% increase.

Graham Capital Management L.P. lifted its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 107.7% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 43,005 shares of the company's stock after purchasing an additional 22,299 shares during the period. Graham Capital Management L.P.'s holdings in Denali Therapeutics were worth $585,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd raised its holdings in shares of Denali Therapeutics by 277.0% during the first quarter. Caitong International Asset Management Co. Ltd now owns 2,111 shares of the company's stock valued at $29,000 after acquiring an additional 1,551 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in shares of Denali Therapeutics during the first quarter worth approximately $41,000. GF Fund Management CO. LTD. purchased a new stake in shares of Denali Therapeutics during the fourth quarter worth approximately $62,000. Point72 Hong Kong Ltd acquired a new position in Denali Therapeutics in the 4th quarter valued at $65,000. Finally, GAMMA Investing LLC lifted its holdings in Denali Therapeutics by 253.8% in the 1st quarter. GAMMA Investing LLC now owns 7,953 shares of the company's stock valued at $108,000 after purchasing an additional 5,705 shares in the last quarter. 92.92% of the stock is currently owned by hedge funds and other institutional investors.

Denali Therapeutics Trading Up 1.2%

DNLI stock traded up $0.18 during trading on Thursday, reaching $14.82. 1,502,280 shares of the stock were exchanged, compared to its average volume of 1,916,940. The company has a current ratio of 10.27, a quick ratio of 10.27 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $2.17 billion, a price-to-earnings ratio of -5.29 and a beta of 1.23. The business has a 50 day moving average price of $14.60 and a 200-day moving average price of $14.48. Denali Therapeutics Inc. has a 1 year low of $10.57 and a 1 year high of $33.33.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.72) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.74) by $0.02. During the same quarter last year, the company posted ($0.59) EPS. On average, research analysts predict that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on DNLI shares. Morgan Stanley dropped their target price on shares of Denali Therapeutics from $33.00 to $30.00 and set an "overweight" rating for the company in a report on Monday, August 18th. TD Cowen raised shares of Denali Therapeutics to a "strong-buy" rating in a research note on Monday, July 28th. Cantor Fitzgerald reissued an "overweight" rating on shares of Denali Therapeutics in a research note on Monday. Finally, Bank of America lowered their target price on Denali Therapeutics from $28.00 to $27.00 and set a "buy" rating on the stock in a report on Monday, May 19th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, Denali Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $33.50.

Insiders Place Their Bets

In other news, insider Alexander O. Schuth sold 2,937 shares of the stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $13.58, for a total transaction of $39,884.46. Following the completion of the transaction, the insider directly owned 242,346 shares in the company, valued at approximately $3,291,058.68. This represents a 1.20% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Ryan J. Watts sold 495,282 shares of the firm's stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $15.00, for a total value of $7,429,230.00. Following the sale, the chief executive officer directly owned 253,071 shares of the company's stock, valued at $3,796,065. The trade was a 66.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 501,962 shares of company stock valued at $7,520,799 over the last quarter. 12.50% of the stock is owned by insiders.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.